Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report) was the target of a large growth in short interest in October. As of October 15th, there was short interest totaling 31,307 shares, a growth of 76.0% from the September 30th total of 17,790 shares. Based on an average daily volume of 54,073 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.7% of the shares of the company are short sold.
Analyst Ratings Changes
Several research firms recently commented on SHPH. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday, July 4th. Weiss Ratings upgraded Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, October 14th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, Shuttle Pharmaceuticals has a consensus rating of “Sell”.
Get Our Latest Stock Report on Shuttle Pharmaceuticals
Shuttle Pharmaceuticals Stock Performance
NASDAQ SHPH traded down $0.08 during trading on Friday, reaching $5.15. The company’s stock had a trading volume of 20,479 shares, compared to its average volume of 43,890. The business’s fifty day moving average price is $4.18 and its 200-day moving average price is $7.13. Shuttle Pharmaceuticals has a twelve month low of $2.58 and a twelve month high of $44.40. The firm has a market cap of $24.51 million, a price-to-earnings ratio of -0.28 and a beta of 0.11.
About Shuttle Pharmaceuticals
Shuttle Pharmaceuticals Holdings, Inc (NASDAQ:SHPH) is a clinical-stage biopharmaceutical company focused on developing therapies designed to improve the effectiveness of radiation treatment for cancer. The company’s research is centered on radiosensitizers, drugs intended to make cancer cells more vulnerable to radiation while potentially limiting damage to surrounding healthy tissue.
Shuttle’s lead candidate is ropidoxuridine, also known as iododeoxyuridine or IUdR, an investigational radiosensitizing agent being evaluated for use with radiotherapy.
Featured Articles
- Five stocks we like better than Shuttle Pharmaceuticals
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Shuttle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shuttle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
